Literature DB >> 22942254

IKK-ε coordinates invasion and metastasis of ovarian cancer.

Sarah Hsu1, Marianne Kim, Lidia Hernandez, Valentina Grajales, Anne Noonan, Miriam Anver, Ben Davidson, Christina M Annunziata.   

Abstract

Inhibitor of IκB kinases (IKK) are key regulators of NF-κB signaling. Three IKK isoforms-α, β, and ε-have been linked to oncogenesis, yet the precise components of NF-κB signaling in ovarian cancer have not yet been dissected. We surveyed 120 ovarian cancer specimens for IKK-ε expression. Notably, cytoplasmic expression was elevated in metastatic lesions relative to primary tumors (P = 0.03). Therefore, we hypothesized that IKK-ε drives ovarian cancer metastasis. IKK-ε was identified previously as a breast cancer oncogene and was associated with poor clinical outcome in ovarian cancer. We now define an ovarian cancer-specific IKK-ε-regulated gene expression signature using stably expressed short hairpin RNA targeting IKK-ε. Pathway analysis of the signature indicated that IKK-ε regulates expression of genes involved in cell motility and inflammation. We further showed that IKK-ε depletion in metastatic ovarian cancer cell lines decreased growth, adhesion, and invasion. Consistently, human xenografts depleted of IKK-ε in mice showed decreased aggressiveness, whereas overexpression of IKK-ε in a less invasive ovarian cancer cell line increased metastasis in vivo. Taken together, these data provide evidence that IKK-ε is a key coordinator of invasion and metastasis programs in ovarian cancer. Inhibition of IKK-ε signaling thus emerges as a viable therapeutic strategy in women whose ovarian cancer shows aberrant activation of this pathway. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22942254      PMCID: PMC3488159          DOI: 10.1158/0008-5472.CAN-11-3993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth.

Authors:  Johanna Soikkeli; Piotr Podlasz; Miao Yin; Pirjo Nummela; Tiina Jahkola; Susanna Virolainen; Leena Krogerus; Päivi Heikkilä; Karl von Smitten; Olli Saksela; Erkki Hölttä
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

2.  Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Authors:  Lídia Hernandez; Sarah C Hsu; Ben Davidson; Michael J Birrer; Elise C Kohn; Christina M Annunziata
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

3.  Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.

Authors:  Christina M Annunziata; Helene Tuft Stavnes; Lilach Kleinberg; Aasmund Berner; Lidia F Hernandez; Michael J Birrer; Seth M Steinberg; Ben Davidson; Elise C Kohn
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

4.  Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.

Authors:  Jian-Ping Guo; Shao-Kun Shu; Lili He; Yi-Chun Lee; Patricia A Kruk; Seija Grenman; Santo V Nicosia; Gil Mor; Michael J Schell; Domenico Coppola; Jin Q Cheng
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

5.  Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Authors:  Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

6.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Authors:  Tomas Bonome; Douglas A Levine; Joanna Shih; Mike Randonovich; Cindy A Pise-Masison; Faina Bogomolniy; Laurent Ozbun; John Brady; J Carl Barrett; Jeff Boyd; Michael J Birrer
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  DNA fingerprinting of the NCI-60 cell line panel.

Authors:  Philip L Lorenzi; William C Reinhold; Sudhir Varma; Amy A Hutchinson; Yves Pommier; Stephen J Chanock; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

8.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.

Authors:  Jessica E Hutti; Rhine R Shen; Derek W Abbott; Alicia Y Zhou; Kam M Sprott; John M Asara; William C Hahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

9.  Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Authors:  Nick Devoogdt; Nabila Rasool; Ebony Hoskins; Fiona Simpkins; Nana Tchabo; Elise C Kohn
Journal:  Cancer Sci       Date:  2009-01-14       Impact factor: 6.716

Review 10.  Management of recurrent ovarian carcinoma: current status and future directions.

Authors:  Lainie P Martin; Russell J Schilder
Journal:  Semin Oncol       Date:  2009-04       Impact factor: 4.929

View more
  30 in total

1.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

2.  Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.

Authors:  Chase L Johnson; Daniel S Green; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

3.  Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.

Authors:  Bipradeb Singha; Himavanth Reddy Gatla; Subrata Manna; Tzu-Pei Chang; Shannon Sanacora; Vladimir Poltoratsky; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2013-12-11       Impact factor: 5.157

4.  Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Authors:  Lidia Hernandez; Marianne K Kim; L Tiffany Lyle; Kristen P Bunch; Carrie D House; Franklin Ning; Anne M Noonan; Christina M Annunziata
Journal:  Gynecol Oncol       Date:  2016-05-28       Impact factor: 5.482

5.  Tryptophan catabolism in epithelial ovarian carcinoma.

Authors:  Lynelle P Smith; Benjamin G Bitler; Jennifer K Richer; Jessica L Christenson
Journal:  Trends Cancer Res       Date:  2019

6.  Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.

Authors:  Banu Eskiocak; Elizabeth A McMillan; Saurabh Mendiratta; Rahul K Kollipara; Hailei Zhang; Caroline G Humphries; Changguang Wang; Jose Garcia-Rodriguez; Ming Ding; Aubhishek Zaman; Tracy I Rosales; Ugur Eskiocak; Michael P Smith; Jessica Sudderth; Kakajan Komurov; Ralph J Deberardinis; Claudia Wellbrock; Michael A Davies; Jennifer A Wargo; Yonghao Yu; Jef K De Brabander; Noelle S Williams; Lynda Chin; Helen Rizos; Georgina V Long; Ralf Kittler; Michael A White
Journal:  Cancer Discov       Date:  2017-04-28       Impact factor: 39.397

7.  A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

Authors:  Nicholas C D'Amato; Thomas J Rogers; Michael A Gordon; Lisa I Greene; Dawn R Cochrane; Nicole S Spoelstra; Travis G Nemkov; Angelo D'Alessandro; Kirk C Hansen; Jennifer K Richer
Journal:  Cancer Res       Date:  2015-09-11       Impact factor: 12.701

8.  NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

Authors:  Carrie D House; Elizabeth Jordan; Lidia Hernandez; Michelle Ozaki; Jana M James; Marianne Kim; Michael J Kruhlak; Eric Batchelor; Fathi Elloumi; Margaret C Cam; Christina M Annunziata
Journal:  Cancer Res       Date:  2017-10-26       Impact factor: 12.701

Review 9.  Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment.

Authors:  Kristen P Zeligs; Monica K Neuman; Christina M Annunziata
Journal:  Clin Cancer Res       Date:  2016-07-15       Impact factor: 12.531

Review 10.  Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers.

Authors:  Lingying Tong; Ye Yuan; Shiyong Wu
Journal:  Adv Drug Deliv Rev       Date:  2014-09-16       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.